Trials / Conditions / Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
4 registered clinical trials studyying Refractory Aggressive B-Cell Non-Hodgkin Lymphoma — 1 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphom NCT06834373 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin NCT05202782 | Northwestern University | Phase 2 |
| Active Not Recruiting | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma NCT05025800 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated Wit NCT04870853 | M.D. Anderson Cancer Center | — |